Cancer nanomedicine meets immunotherapy: opportunities and challenges

• 作者: Alexandros Marios Sofias Bruno De Geest Eduardo Ruiz-Hernandez Fabian Kiessling Gert Storm Hai-jun Yu Qingxue Sun Roy van der Meel Twan Lammers Wim E.Hennink Xiangyang Bai Yang Shi
• 来源期刊: 中国药理学报（英文版）
• 关键词: nanomedicine immunotherapy targeting combination therapy clinical translation
• 年，卷（期）: 2020,（7）
• 页码范围: 954-958
• 页数: 5页
• 语种: 英文

摘要

Cancer nanomedicines have shown promise in combination immunotherapy,thus far mostly preclinically but also already in clinical trials.Combining nanomedicines with immunotherapy aims to reinforce the cancer-immunity cycle,via potentiating key steps in the immune reaction cascade,namely antigen release,antigen processing,antigen presentation,and immune cell-mediated killing.Combination nano-immunotherapy can be realized via three targeting strategies,i.e.,by targeting cancer cells,targeting the tumor immune microenvironment,and targeting the peripheral immune system.The clinical potential of nano-immunotherapy has recently been demonstrated in a phase Ⅲ trial in which nano-albumin paclitaxel (Abraxane(R)) was combined with atezolizumab (Tecentriq(R)) for the treatment of patients suffering from advanced triple-negative breast cancer.In the present paper,besides strategies and initial (pre)clinical success stories,we also discuss several key challenges in nano-immunotherapy.Taken together,nanomedicines combined with immunotherapy are gaining significant attention,and it is anticipated that they will play an increasingly important role in clinical cancer therapy.